Quviviq
- Prescription status not stated
- Pain, sleep, mood, epilepsy and the brain
- Active substance
- Daridorexant
- Made by
- Idorsia Pharmaceuticals Deutschland GmbH
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.
From the official label · 2026-09-30 · European Medicines Agency
How it works
From the US prescribing label for the same active substance (QUVIVIQ). It describes the substance, not this exact product.
The mechanism of action of daridorexant in the treatment of insomnia is presumed to be through antagonism of orexin receptors.
The orexin neuropeptide signaling system plays a role in wakefulness.
Daridorexant undergoes extensive metabolism and is primarily metabolized by CYP3A4 (89%).
Effect of food In healthy subjects, a high-fat and high-calorie meal delayed the T max by 1.3 hours and decreased the C max by 16%, but did not affect the total exposure (AUC).
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-02-26
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Idorsia Pharmaceuticals Deutschland GmbH |
|---|---|
| Active substance | Daridorexant |
| Used in | Pain, sleep, mood, epilepsy and the brain |
| Classification | N05CJ03 · Pain, sleep, mood, epilepsy and the brain |
| Additional monitoring ▼ | Yes — under additional monitoring (black triangle). Report suspected side effects. |
| Authorised on | 2022-04-29 |
| Last updated by the regulator | 2026-03-12 |
| EMA product number | EMEA/H/C/005634 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).